A Study to Evaluate the Safety and Feasibility of Exablate Model 4000 Type-2 to temporarily mediate Blood-Brain Barrier Disruption (BBBD) in patients with suspected infiltrating glioma in the setting of planned surgical interventions
Enrolling By Invitation
18 years - 99 years
All
Phase
N/A
3 participants needed
1 Location
Brief description of study
The goal of this prospective, non-randomized, single-arm study is to evaluate the safety and feasibility of using ExAblate Model 4000 Type-2 Neuro-System as a tool to disrupt the blood brain barrier in a temporary and localized fashion in patients with suspected infiltrating glioma undergoing planned surgical interventions.
Eligibility of study
You may be eligible for this study if you meet the following criteria:
- Conditions: surgery
-
Age: 18 years - 99 years
-
Gender: All
Updated on
04 Aug 2024.
Study ID: 833809
If you need assistance finding a non-cancer clinical research study or if you have any questions, please email psom-ocr@pobox.upenn.edu
For Cancer trials contact Penn Medicine's Cancer Trial Navigator at: PMCancerResearch@pennmedicine.upenn.edu or 215-349-8245
